Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Shire plc

7 Jan 2019 12:56

RNS Number : 4016M
Susquehanna Ireland Ltd
07 January 2019
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Susquehanna International Holdings LLC ("SIHL")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shire plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

04/01/2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Takeda Pharmaceutical Company Limited

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares ISIN: JE00B2QKY057

ADRs ISIN: US82481R1068

(Each ADR converts to 3 Ordinary Shares)

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

8,527,018

0.929%

0

0%

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

1,709,600

0.19%

481,400

0.05%

 

TOTAL:

10,236,618

1.115%

481,400

0.05%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities (ADR's converted at 3 shares to 1 ADR ratio)

Price per unit

ADR

PURCHASE

900

177.56

ADR

PURCHASE

1200

177.625

ADR

PURCHASE

3300

177.33

ADR

PURCHASE

2808

177.68

ADR

PURCHASE

600

177.97

ADR

PURCHASE

300

177.8925

ADR

PURCHASE

2448

176.84

ADR

PURCHASE

5100

177.58

ADR

PURCHASE

600

178.06

ADR

PURCHASE

900

177.61

ADR

PURCHASE

5073

177.69

ADR

PURCHASE

35580

177.6

ADR

PURCHASE

6576

178.1

ADR

PURCHASE

40839

177.95

ADR

PURCHASE

7800

177.96

ADR

PURCHASE

900

177.645

ADR

PURCHASE

1200

178.13

ADR

PURCHASE

900

177.54

ADR

PURCHASE

900

177.55

ADR

PURCHASE

300

177.52

ADR

PURCHASE

5700

177.94

ADR

PURCHASE

1500

177.92

ADR

PURCHASE

17700

177.65

ADR

PURCHASE

240

177.975

ADR

PURCHASE

6303

177.93

ADR

PURCHASE

1200

178.07

ADR

PURCHASE

300

176.82

ADR

PURCHASE

5703

176.83

ADR

PURCHASE

300

177.925

ADR

PURCHASE

300

177.595

ADR

PURCHASE

600

177.67

ADR

PURCHASE

900

177.89

ADR

PURCHASE

3297

176.81

ADR

PURCHASE

1500

177.57

ADR

PURCHASE

300

177.525

ADR

PURCHASE

6603

177.59

ADR

PURCHASE

300

177.53

ADR

PURCHASE

300

177.945

ADR

PURCHASE

300

177.995

ADR

PURCHASE

24282

177.62

ADR

PURCHASE

15000

177.15

ADR

PURCHASE

4365

177.2

ADR

PURCHASE

300

177.505

ADR

PURCHASE

11100

178.14

ADR

PURCHASE

3300

177.91

ADR

PURCHASE

600

176.99

ADR

PURCHASE

5118

177.63

ADR

PURCHASE

4470

178.09

ADR

PURCHASE

12327

177.7

ADR

PURCHASE

8100

177

ADR

PURCHASE

4830

177.98

ADR

PURCHASE

300

178.139

ADR

PURCHASE

303

176.825

ADR

PURCHASE

972

176.85

ADR

PURCHASE

900

178.08

ADR

PURCHASE

40860

178

ADR

PURCHASE

19200

177.9

ADR

PURCHASE

7830

177.99

ADR

SALE

-2283

179.74

ADR

SALE

-300

179.75

 

 

 

 

ORDINARY

SALE

-150000

46.9

ORDINARY

SALE

-14000

47.2

ORDINARY

SALE

-56000

47

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

07/01/2019

Contact name:

Diana Taraseviciute / Damian Kenny

Telephone number*:

+353-1-247-8480

+ 353-1-802-8089

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

 

 

 

 

 

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

Full name of person making disclosure:

Susquehanna International Holdings LLC ("SIH LLC")

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

Shire Plc

 

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option on ord

PUT

Written

448

4000

American

18-Jan-19

Option on ord

PUT

Written

228

4200

American

18-Jan-19

Option on ord

PUT

Written

150

3800

American

15-Mar-19

Option on ord

PUT

Written

141

3800

American

15-Mar-19

Option on ord

PUT

Written

106

3800

American

18-Jan-19

Option on ord

PUT

Written

100

3200

American

20-Dec-19

Option on ord

PUT

Written

25

4400

American

18-Jan-19

Option on ord

PUT

Written

25

4400

American

15-Mar-19

Option on ord

PUT

Written

20

3000

American

21-Jun-19

Option on ord

PUT

Written

15

4400

American

18-Jan-19

Option on ord

PUT

Written

15

3200

American

19-Jun-20

Option on ord

PUT

Written

10

2800

American

18-Jan-19

Option on ord

PUT

Written

10

4600

American

18-Jan-19

Option on ord

PUT

Written

10

3000

American

15-Feb-19

Option on ord

PUT

Written

9

3200

American

15-Feb-19

Option on ord

PUT

Written

5

4000

American

15-Feb-19

Option on ord

PUT

Written

5

3200

American

15-Mar-19

Option on ord

PUT

Written

5

4000

American

20-Sep-19

Option on ADR

PUT

Written

3

150

American

18-Apr-19

Option on ord

PUT

Written

2

4200

American

15-Feb-19

Option on ADR

PUT

Written

1

160

American

18-Jan-19

Option on ADR

CALL

Purchased

1

150

American

18-Apr-19

Option on ord

CALL

Purchased

5

5200

American

20-Sep-19

Option on ord

CALL

Purchased

7

4000

American

18-Jan-19

Option on ADR

CALL

Purchased

8

155

American

18-Apr-19

Option on ord

CALL

Purchased

9

4000

American

15-Mar-19

Option on ord

CALL

Purchased

9

5200

American

18-Apr-19

Option on ord

CALL

Purchased

14

5200

American

15-Feb-19

Option on ADR

CALL

Purchased

19

200

American

18-Jan-19

Option on ord

CALL

Purchased

45

4800

American

18-Jan-19

Option on ord

CALL

Purchased

100

4000

American

20-Dec-19

Option on ord

CALL

Purchased

132

4800

American

15-Mar-19

Option on ord

CALL

Written

70

4400

American

15-Mar-19

Option on ord

PUT

Written

50

4200

American

18-Jan-19

Option on ord

CALL

Written

47

4600

American

18-Jan-19

Option on ord

CALL

Written

18

4600

American

15-Mar-19

Option on ord

CALL

Written

10

5600

American

20-Dec-19

Option on ord

CALL

Written

5

4400

American

18-Jan-19

Option on ord

CALL

Written

5

5600

American

19-Jun-20

Option on ord

CALL

Written

5

4800

American

20-Dec-19

Option on ord

PUT

Purchased

1

4400

American

15-Feb-19

Option on ord

PUT

Purchased

1

4400

American

18-Apr-19

Option on ADR

PUT

Purchased

1

160

American

18-Jan-19

Option on ADR

PUT

Purchased

1

160

American

18-Apr-19

Option on ord

PUT

Purchased

2

3600

American

15-Mar-19

Option on ADR

PUT

Purchased

3

150

American

18-Apr-19

Option on ADR

PUT

Purchased

3

155

American

18-Apr-19

Option on ord

PUT

Purchased

4

3600

American

18-Jan-19

Option on ord

PUT

Purchased

5

2000

American

18-Jan-19

Option on ord

PUT

Purchased

5

2400

American

18-Jan-19

Option on ord

PUT

Purchased

5

3200

American

18-Jan-19

Option on ord

PUT

Purchased

5

3800

American

21-Jun-19

Option on ord

PUT

Purchased

7

3400

American

15-Feb-19

Option on ord

PUT

Purchased

10

4800

American

15-Mar-19

Option on ord

PUT

Purchased

13

4200

American

15-Mar-19

Option on ord

PUT

Purchased

16

4000

American

15-Mar-19

Option on ord

PUT

Purchased

45

4000

American

20-Dec-19

Option on ord

CALL

Written

200

5200

American

18-Jan-19

 

3. AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

 

The currency of all prices and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETBRMTTMBAMBJL
Date   Source Headline
8th Jan 20195:30 pmGNWDirector/PDMR Shareholding
8th Jan 20193:20 pmRNSForm 8.3 - Shire plc
8th Jan 20193:19 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20193:13 pmRNSForm 8.3 - Shire plc
8th Jan 20193:07 pmRNSForm 8.5 (EPT/NON-RI)
8th Jan 20192:28 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:23 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:21 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20191:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20191:27 pmRNSForm 8.3 - Shire plc
8th Jan 201912:31 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201912:29 pmRNSForm 8.3 - Takeda Pharmaceutical
8th Jan 201912:27 pmRNSForm 8.3 - Shire plc
8th Jan 201911:42 amRNSForm 8.5 (EPT/NON-RI)
8th Jan 201911:33 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
8th Jan 201910:49 amRNSForm 8.5 (EPT/RI)
8th Jan 201910:41 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201910:26 amRNSForm 8.5 (EPT/RI)- Shire plc
8th Jan 20199:51 amRNSForm 8.3 - Shire Plc
8th Jan 20198:44 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
8th Jan 20197:00 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20197:00 amGNWScheme becomes effective
7th Jan 20195:00 pmGNWHolding(s) in Company
7th Jan 20193:42 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Jan 20193:20 pmRNSForm 8.3 - Shire plc
7th Jan 20193:02 pmRNSForm 8.3 - Shire plc
7th Jan 20193:00 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 20193:00 pmRNSForm 8.3 - Shire plc
7th Jan 20192:59 pmRNSForm 8.3 - Takeda Pharmaceutical
7th Jan 20192:50 pmPRNForm 8.3 - Shire Plc
7th Jan 20192:49 pmRNSForm 8.3 - Shire plc
7th Jan 20192:47 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20192:45 pmBUSForm 8.3 - Shire plc
7th Jan 20191:55 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20191:54 pmRNSForm 8.3 - Shire plc
7th Jan 20191:39 pmRNSForm 8.3 - [Shire Plc]
7th Jan 20191:32 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 20191:29 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 201912:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201912:56 pmRNSForm 8.3 - Shire plc
7th Jan 201912:42 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 201911:52 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:43 amBUSForm 8.3 - SHIRE PLC
7th Jan 201911:30 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:27 amRNSForm 8.3 - Shire plc
7th Jan 201911:01 amRNSForm 8.5 (EPT/RI)- Shire plc
7th Jan 201910:59 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
7th Jan 201910:35 amRNSForm 8.5 - Shire plc
7th Jan 201910:16 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
7th Jan 201910:13 amRNSForm 8.5 (EPT/RI) - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.